VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. du Bois on Pazopanib in Advanced Ovarian Cancer

Andreas du Bois, MD
Published: Saturday, Jun 01, 2013

Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

In this trial, pazopanib following initial successful chemotherapy extended progression-free survival by an average of 5.6 months, compared to placebo.

To read more about this study >>>

<<< View more from the 2013 ASCO Annual Meeting

Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

In this trial, pazopanib following initial successful chemotherapy extended progression-free survival by an average of 5.6 months, compared to placebo.

To read more about this study >>>

<<< View more from the 2013 ASCO Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x